Comparative Toxicities and Pharmacokinetics of Intrathecal Lipid (Amphotericin B Colloidal Dispersion) and Conventional Deoxycholate Formulations of Amphotericin B in Rabbits-Reference-Cited by-同舟云学术

Comparative Toxicities and Pharmacokinetics of Intrathecal Lipid (Amphotericin B Colloidal Dispersion) and Conventional Deoxycholate Formulations of Amphotericin B in Rabbits

Published:2001-02 Issue:2 Volume:45 Page:612-615
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Clemons Karl V.¹²³,Sobel Raymond A.⁴⁵,Williams Paul L.¹⁶,Stevens David A.¹²³

Affiliation:

1. California Institute for Medical Research,1 and

2. Department of Medicine, Division of Infectious Diseases,2 Santa Clara Valley Medical Center, San Jose, California 95128;

3. Department of Medicine, Division of Infectious Diseases and Geographic Medicine,3 and

4. Department of Pathology,4 Stanford University, Stanford, California 94305;

5. Palo Alto Veterans Affairs Health Care System,5 Palo Alto, California 94304; and

6. Kaweah Delta District Hospital, Visalia, CA 932916

Abstract

ABSTRACT The lipid formulation of amphotericin B, Amphotec (ABCD), has not been used intrathecally. After a single intrathecal dose or after four doses, conventionally formulated deoxycholate amphotericin B (AMB) (Fungizone) resulted in higher levels of amphotericin B in the cerebrospinal fluid of rabbits than did ABCD. Clinically and histologically, ABCD was about threefold less toxic than AMB after a single dose and 3- to 30-fold less toxic after multiple dosing. These data are encouraging for the potential use of ABCD as an intrathecal treatment.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.45.2.612-615.2001

Reference19 articles.

1. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis

2. Amphotericin B-induced myelopathy.;Carnevale N. T.;Arch. Intern. Med.,1980

3. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis?;Dewsnup D. H.;Ann. Intern. Med.,1996

4. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats

5. Amphotericin B: 30 years of clinical experience.;Gallis H. A.;Rev. Infect. Dis.,1990

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Experiences with Intrathecal Administration of Amphotericin B Liposomal Formulation at a Neurosurgical Center;CNS Drugs;2024-01-25

2. Amphotericin B: A drug of choice for Visceral Leishmaniasis;Acta Tropica;2022-11

3. Pharmacokinetics and Safety of Single-Dose Amphotericin B Colloidal Dispersion in Healthy Chinese Subjects and Population Pharmacokinetic/Pharmacodynamic Analysis to Inform Clinical Efficacy in Invasive Infections Caused by Candida albicans;Clinical Therapeutics;2021-11

4. A Critical Review of Analytical Methods for Quantification of Amphotericin B in Biological Samples and Pharmaceutical Formulations;Critical Reviews in Analytical Chemistry;2020-09-03

5. Safety and tolerability of intrathecal liposomal amphotericin B (AmBisome) for cryptococcal meningitis: a retrospective study in HIV-infected patients;Therapeutic Advances in Infectious Disease;2018-06-12